Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Ipsen
(OTCPK:IPSEF)
Intraday
$117.60
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$117.60
0
[0.00%]
At close: Mar 14
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Ipsen Stock (OTC:IPSEF)
Ipsen Stock (OTC: IPSEF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, April 02, 2024
Ipsen And Sutro Biopharma Enter Exclusive Global Licensing Agreement For An ADC Targeting Solid Tumors
Benzinga Newsdesk
-
Apr 2, 2024, 1:49AM
Wednesday, March 27, 2024
Merrimack Secures $225M Milestone Payment From Ipsen; Says It Is Unlikely That Any Additional Milestone Payments Will Become Payable
Benzinga Newsdesk
-
Mar 27, 2024, 4:34PM
Monday, August 21, 2023
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
Vandana Singh
-
Aug 21, 2023, 2:57PM
Monday, May 22, 2023
What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
Vandana Singh
-
May 22, 2023, 4:20PM
Monday, January 09, 2023
France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline
Vandana Singh
-
Jan 9, 2023, 6:24AM
Wednesday, November 09, 2022
Why Merrimack Shares Are Surging Over 200% Today?
Vandana Singh
-
Nov 9, 2022, 9:04AM
Wednesday, August 03, 2022
Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure
Vandana Singh
-
Aug 3, 2022, 11:49AM
Monday, June 27, 2022
Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why
Vandana Singh
-
Jun 27, 2022, 6:45AM
Tuesday, May 03, 2022
Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer
Vandana Singh
-
May 3, 2022, 5:54AM
Friday, March 25, 2022
EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer
Vandana Singh
-
Mar 25, 2022, 1:41PM
Monday, January 24, 2022
Ipsen's Sohonos Scores Canadian Approval For Rare Connective Tissue Disease
Vandana Singh
-
Jan 24, 2022, 5:54AM
Friday, December 17, 2021
Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful
Vandana Singh
-
Dec 17, 2021, 6:25AM
Friday, August 13, 2021
Ipsen Stock Declines After Pulling Rare Disease Application
Vandana Singh
-
Aug 13, 2021, 10:48AM
Monday, August 02, 2021
Exicure Stock Surges On Over $1B Option Licensing Pact With Ipsen For Rare Neurodegenerative Disorders
Vandana Singh
-
Aug 2, 2021, 7:24AM
Monday, June 28, 2021
Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer
Vandana Singh
-
Jun 28, 2021, 8:40AM
Friday, February 26, 2021
European Medicines Agency's CHMP Backs Approval Of Cabometyx/Opdivo Combo In Kidney Cancer
Vandana Singh
-
Feb 26, 2021, 12:55PM
Tuesday, August 30, 2011
Earnings Roundup
Benzinga
-
Aug 30, 2011, 9:08AM
Ipsen Reports 21% Surge In First-Half Net Income
Benzinga
-
Aug 30, 2011, 5:04AM
